Browse studies

Find your next paid study

27,352 recruiting studies available now

Automating Tobacco Cessation in Primary Care Via EHR Integration: A Non-Randomized Trial

This study focuses on improving how primary care teams identify patients who smoke and offer access to nicotine replacement therapy, or NRT. NRT includes medic…

Tobacco UseTobacco Use Cessation

Estimated

~$10 – $750

Actual pay is set by the research site.

University of PennsylvaniaNCT07735286

Phase 3

A Phase 3, Double-Blind, Randomized, Two-Period, Multicenter, Placebo-Controlled, Efficacy and Safety Study of JNT-517 for the Treatment of Participants With Phenylketonuria

This Phase 3 study will evaluate the safety, effectiveness, tolerability, and how the body processes JNT-517 in children, adolescents, and adults with phenylke…

Phenylketonuria

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Otsuka Pharmaceutical Development & Commercialization, Inc.NCT06971731

Phase 2

A Phase 2 Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine

The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infus…

Methamphetamine IntoxicationMethamphetamine DisordersMethamphetamine Abuse

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Clear Scientific, Inc.NCT06721494

Observational

Digital Screening and Brief Intervention for Perinatal Substance Use in Home Visiting

The goal of this study is to learn about whether digital screening and brief intervention can help address substance use in postpartum mothers who are enrolled…

Substance Use

Estimated

~$10 – $750

Actual pay is set by the research site.

The National Center on Addiction and Substance Abuse at Columbia UniversityNCT06624332

Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Newly Diagnosed AML With an NPM1 Mutation

The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations c…

Acute Myeloid Leukemias

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Syndax PharmaceuticalsNCT07211958

Phase 1

A Phase 1, Double-blinded, Randomized, Dose-repeating, Placebo-controlled, Cross-over Study to Assess the Safety and Preliminary Efficacy of Allogeneic ULSC on Disease Severity in Facioscapulohumeral Muscular Dystrophy (FSHD)

The goal of this clinical trial is to learn about how an umbilical cord lining-derived stem cell product (ULSC) performs when treating Facioscapulohumeral Musc…

FSHD - Facioscapulohumeral Muscular Dystrophy

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Restem, LLC.NCT07086521

Phase 4

Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy (MCPAIN)

The research team will perform a comparative-effectiveness sequential, multiple assignment, randomized trial in painful diabetic neuropathy (PDN) patients for …

Painful Diabetic Neuropathy (PDN)Diabetic Nephropathies

Estimated

~$25 – $1,000

Actual pay is set by the research site.

University of MichiganNCT07795593

Phase 1

A Phase I Trial Combining Triapine With Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or as…

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT06860594

Phase 2

Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EC-18 in Preventing the Progression of COVID-19 Infection to Severe Pneumonia or ARDS

A trial of EC-18 in patients with mild/moderate pneumonia due to COVID-19

Covid19 Pneumonia

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Enzychem Lifesciences CorporationNCT04569227

Phase 1

A Phase Ia/Ib, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic of UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with rela…

Relapsed/Refractory B-cell Malignancies

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Ubix Therapeutics, Inc.NCT06590961

Phase 1

Phase Ib, Open-label Study of Add on Therapy With CK0804 in Participants With Myelofibrosis, With Suboptimal Response to Ruxolitinib

To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib

Myelofibrosis

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Cellenkos, Inc.NCT05423691

Phase 2

A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers (I-MAC)

The goal of this study is to evaluate the efficacy and safety of Ivonescimab in participants with advanced, metastatic salivary gland cancers. The name of the…

Salivary Gland CancerAdvanced Salivary Gland CarcinomaMetastatic Salivary Gland Cancer+1 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Dana-Farber Cancer InstituteNCT06805617